Vor Biopharma Inc. VOR
We take great care to ensure that the data presented and summarized in this overview for Vor Biopharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VOR
View all-
Ra Capital Management, L.P. Boston, MA22.7MShares$17.5 Million0.22% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA6.36MShares$4.9 Million1.77% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT2.47MShares$1.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$1.5 Million0.0% of portfolio
-
Cowen And Company, LLC1.22MShares$939,8540.02% of portfolio
-
Johnson & Johnson New Brunswick, NJ1.07MShares$827,4860.24% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny756KShares$582,1280.0% of portfolio
-
Sarissa Capital Management LP Greenwich, CT618KShares$475,8600.11% of portfolio
-
Black Rock Inc. New York, NY498KShares$383,2250.0% of portfolio
-
Mai Capital Management476KShares$366,4360.0% of portfolio
Latest Institutional Activity in VOR
Top Purchases
Top Sells
About VOR
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VOR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 06
2024
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
875
-0.51%
|
$0
$0.86 P/Share
|
|
Nov 06
2024
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,361
-0.3%
|
$0
$0.86 P/Share
|
|
Nov 06
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
999
-1.08%
|
$0
$0.86 P/Share
|
|
Nov 06
2024
|
Amy Quinlan Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
206
-0.41%
|
$0
$0.86 P/Share
|
|
Nov 01
2024
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,751
-0.35%
|
$0
$0.8 P/Share
|
|
Nov 01
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,146
-1.22%
|
$0
$0.8 P/Share
|
|
Nov 01
2024
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
986
-0.57%
|
$0
$0.8 P/Share
|
|
Nov 01
2024
|
Amy Quinlan Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
343
-0.67%
|
$0
$0.8 P/Share
|
|
Sep 03
2024
|
Amy Quinlan Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
4,402
-7.97%
|
$0
$0.83 P/Share
|
|
Sep 03
2024
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,657
-1.57%
|
$0
$0.83 P/Share
|
|
Sep 03
2024
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
5,576
-3.14%
|
$0
$0.83 P/Share
|
|
Aug 06
2024
|
Amy Quinlan Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
206
-0.37%
|
$0
$0.87 P/Share
|
|
Aug 06
2024
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,361
-0.29%
|
$0
$0.87 P/Share
|
|
Aug 06
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
999
-1.05%
|
$0
$0.87 P/Share
|
|
Aug 06
2024
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
876
-0.49%
|
$0
$0.87 P/Share
|
|
Aug 01
2024
|
Amy Quinlan Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
343
-0.61%
|
$0
$0.94 P/Share
|
|
Aug 01
2024
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
985
-0.55%
|
$0
$0.94 P/Share
|
|
Aug 01
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,146
-1.19%
|
$0
$0.94 P/Share
|
|
Aug 01
2024
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,751
-0.34%
|
$0
$0.94 P/Share
|
|
Jun 03
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
14,645
-13.23%
|
$14,645
$1.39 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 316K shares |
|---|
| Payment of exercise price or tax liability | 83.4K shares |
|---|---|
| Open market or private sale | 14.6K shares |